Klaria Pharma files third-generation patent to extend exclusivity for sumatriptan alginate film

Swedish pharmaceutical company Klaria Pharma Holding AB (Nasdaq First North Growth Market:KLAR) said on Thursday that it has filed a third-generation patent application for its sumatriptan alginate film, aiming to secure global market exclusivity until at least 2045.

This filing builds on existing first- and second-generation patents.

The product, which received market authorisation in the European Union last year, is being prepared for commercial launch in partnership with CNX. The new patent application reflects advancements from recent years in manufacturing, quality control and testing.

Klaria's earlier patents include protection of the underlying alginate film technology and the specific use of sumatriptan in this format, with approvals already granted in major markets such as the United States, European Union, Canada and Australia. Applications remain pending in China and Hong Kong.

With extended exclusivity, Klaria aims to enhance the product's lifetime value and market penetration, while increasing competitive barriers. According to Klaria, sumatriptan is widely recognised as the most effective acute migraine treatment, recommended by the American Academy of Family Physicians.

The sumatriptan alginate film targets a growing global market where migraines remain underdiagnosed and undertreated, particularly among women.



Published in Nordic Business Report on Thursday, 03 July 2025
Copyright (C) 2025, M2 Communications Ltd.


Other Latest Headlines